Article · Wikipedia archive · Last revised Jul 21, 2026

CB-86

CB-86 is a synthetic cannabinoid drug which was developed as a hybrid between classical/nonclassical cannabinoids such as THC and CP 47,497 with endogenous cannabinoid ligands such as anandamide. It acts as a partial agonist at CB1 receptors with a Ki of 5.6 nM, and an antagonist of CB2 receptors with a Ki of 7.9 nM. It has analgesic effects in studies on mice.

Last revised
Jul 21, 2026
Read time
≈ 1 min
Length
129 w
Citations
1
Source
Wikipedia ↗
CB-86
Identifiers
  • N-cyclopropyl-8-[3-hydroxy-5-(2-methyloctan-2-yl)phenoxy]octanamide
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC26H43NO3
Molar mass417.634 g·mol−1
3D model (JSmol)
  • CCCCCCC(C)(C)C1=CC(=CC(=C1)OCCCCCCCC(=O)NC2CC2)O
  • InChI=1S/C26H43NO3/c1-4-5-6-11-16-26(2,3)21-18-23(28)20-24(19-21)30-17-12-9-7-8-10-13-25(29)27-22-14-15-22/h18-20,22,28H,4-17H2,1-3H3,(H,27,29)
  • Key:PVAOGZXUOOHSMN-UHFFFAOYSA-N

CB-86 is a synthetic cannabinoid drug which was developed as a hybrid between classical/nonclassical cannabinoids such as THC and CP 47,497 with endogenous cannabinoid ligands such as anandamide. It acts as a partial agonist at CB1 receptors with a Ki of 5.6 nM, and an antagonist of CB2 receptors with a Ki of 7.9 nM. It has analgesic effects in studies on mice.1

See also

See also

References

References

  1. Brizzi A, Brizzi V, Cascio MG, Corelli F, Guida F, Ligresti A, et al. (April 2009). "New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo". Journal of Medicinal Chemistry. 52 (8): 2506–2514. doi:10.1021/jm8016255. PMID 19331413.